Background: The AJCC recently published the 8th edition of its cancer staging system. Significant changes were made to the staging algorithm for soft tissue sarcoma (STS) of the extremities or trunk, including the addition of 2 additional T (size) classifications in lieu of tumor depth and grouping lymph node metastasis (LNM) with distant metastasis as stage IV disease. Whether these changes improve staging system performance is questionable. Patients and Methods: This retrospective cohort analysis of 21,396 adult patients with STS of the extremity or trunk in the SEER database compares the AJCC 8th edition staging system with the 7th edition and a newly proposed staging algorithm using a variety of statistical techniques. The effect of tumor size on disease-specific survival was assessed by flexible, nonlinear Cox proportional hazard regression using restricted cubic splines and fractional polynomials. Results: The slope of covariate-adjusted log hazards for sarcoma-specific survival decreases for tumors >8 cm in greatest dimension, limiting prognostic information contributed by the new T4 classification in the AJCC 8th edition. Anatomic depth independently provides significant prognostic information. LNM is not equivalent to distant, non-nodal metastasis. Based on these findings, an alternative staging system is proposed and demonstrated to outperform both AJCC staging schemes. The analyses presented also disclose no evidence of improved clinical performance of the 8th edition compared with the previous edition. Conclusions: The AJCC 8th edition staging system for STS is no better than the previous 7th edition. Instead, a proposed staging system based on histologic grade, tumor size, and anatomic depth shows significantly higher predictive accuracy, with higher model concordance than either AJCC staging system. Changes to existing staging systems should improve the performance of prognostic models. Until such improvements are documented, AJCC committees should refrain from modifying established staging schemes.
Considerable changes in the clinical and pathologic staging of soft tissue sarcoma (STS) are presented in the 8th edition of the AJCC Cancer Staging Manual. 1 There are some obvious improvements, such as the creation of separate staging schemes for different anatomic locations. It is well-known that STSs arising within the extremities or trunk, retroperitoneum or abdominopelvic cavities, or the head/neck region show inherent differences in their biological behavior and clinical courses. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] However, other changes in the 8th edition, such as creating 2 additional T (size) classifications in lieu of tumor depth and grouping lymph node metastasis posed modifications to a staging system demonstrate improved performance of prognostic models, AJCC committees should refrain from implementing alterations of staging schemes.
Patients and Methods
The SEER program of the NCI collects and publishes cancer incidence and survival data from 20 geographically diverse, population-based cancer registries representing approximately 28% of the US population. The SEER database was queried for malignant soft tissue tumors arising at all anatomic sites diagnosed from 1973 to 2013 to ensure all possible cases were extracted (see eAppendix 1 and supplemental eTable 1, available with this article at JNCCN.org, for SEER*Stat version used, database queried, search criteria, histologic and anatomic site categorizations, and details regarding exclusion of cases). Exclusion criteria included histologic diagnosis not recommended for AJCC staging, anatomic sites other than soft tissue of the extremity or trunk, cases diagnosed before 1990, cases without confirmation of diagnosis by histopathologic or cytopathologic examination, patients <18 years of age, and cases in which primary curative surgery was either not performed or could not be confirmed. Cases with tumor size <0.5 cm (n=65) were excluded based on sparsity of data in this size range. Cases with tumor size listed as >40 cm (n=75) were excluded for the same reason in addition to apparent rounding to the nearest 5 cm. The final cohort consisted of 21, 396 cases. This population-based study of a publicly available deidentified patient database was exempt from Institutional Research Board approval.
Variables downloaded included information on patient age, sex, year of diagnosis, anatomic site, site-specific disease extent, lymph node and/or distant metastasis at diagnosis, AJCC TNM stage (Table 1), 14, 15 histologic subtype of sarcoma, histologic grade, tumor size, primary treatment, disease-free survival status, and follow-up interval. Cases with follow-up intervals recorded as 0 months were recoded as 0.5 months if incomplete dates were available but survival of at least 1 day was documented (n=232); other cases with missing follow-up data (n=21), complete dates available with 0 days of survival (likely autopsy entries; n=44), or incomplete Stage IA  T1; N0; M0; G1   Stage IB  T2, T3, T4; N0; M0; G1   Stage II  T1; N0; M0; G2/3   Stage IIIA  T2; N0; M0; G2/3   Stage IIIB  T3, T4; N0; M0; G2/3 Stage IV Any T; N1; M0; any G Any T; any N; M1; any G dates available with 0 days of follow-up possible (n=5) were excluded.
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Statistical Analyses
The effect of sarcoma size on disease-specific survival (DSS) was assessed by flexible Cox proportional hazard regression using restricted cubic splines 16 and fractional polynomials. [17] [18] [19] [20] For spline models, 5 knots were set at default locations. 21 Powers searched in 1-and 2-degree fractional polynomials ranged from -2 to 3, including square roots and the natural logarithm of the independent variable. The relative prognostic impact of predictive factors was assessed using a nomogram. 22 Several different statistical methods were applied to compare different staging schemes. KaplanMeier curves were plotted and compared to assess the degree of discrimination between tumor stage categories. Subsequent pairwise comparisons of adjacent staging categories were performed using the Sidak method for multiple comparisons. The predictive accuracy of each staging system for determining 5-year DSS was evaluated by comparing the areas under receiver operating characteristic (ROC) curves generated from logistic regression. Three different concordance indices were also used for model comparisons: Harrell's c, 23, 24 Somers' D, 25 and Gönen and Heller's K. 26 Because the first 2 indices neglect censored outcomes that occur before events, 27 this potential source of bias was minimized by excluding 5,089 patients censored before 5 years of clinical follow-up and comparing the differences of the estimated indices between nested regression models. These statistics were computed using bootstrap methods (500 replications) on separate training and validation sets semirandomly created after sorting on each staging system to ensure relatively similar percentages of each tumor stage in the bootstrapped samples. Gönen and Heller's K calculates the probability that a patient with a higher hazard ratio (HR) dies earlier than one with a lower HR. This index is based on model parameters and observed distributions of covariates and is independent of censoring bias. Therefore, all study cases were used to compute Gönen and Heller's K via separate bootstrapping methods. Finally, the amount of variation in observed outcomes explained by the various regression models was assessed using O'Quigley's ρ ; standard errors of these estimates were obtained using bootstrap techniques (500 replications). The Bayesian information criterion based on the number of deaths secondary to sarcoma, and not simply overall sample size, was also calculated for each staging system as a measure of model fit. [30] [31] [32] [33] All results are from 2-sided hypothesis tests using α=0.05. All analyses were performed using Stata v13.1 (Stata Corp., College Station, TX).
Results
The SEER Cohort of Sarcomas Arising in the Extremities and Trunk
Clinicopathologic characteristics of the entire cohort (N=21,396) are provided in supplemental eTable 2. Mean age was 59 years (SD, 18 years; median, 59 years; interquartile range [IQR], 45-73 years). Mean tumor size was 8.7 cm (SD, 6.5 cm; median, 7 cm; IQR, 4-12 cm). Median follow-up for censored patients was 63 months (range, 0.5-287 months). A total of 4,050 patients (19%) died of sarcoma a median of 22 months after surgical resection (range, 0.5-258 months).
Survival Analysis
All variables tested were statistically significant in univariate sarcoma-specific survival analysis, with profound effects seen for histologic grade and distant metastasis, as expected (supplemental eTable 3). Because HRs for radiation therapy before, during, or after surgical resection were not significantly different from each other (data not shown), these groups were combined for multivariable analysis. The only variable that lost statistical significance on multivariable regression was neoadjuvant chemotherapy, and therefore this variable was excluded. Unless otherwise stated, all subsequent multivariable regression analyses included the covariates listed in supplemental eTable 3.
Assessing Size as a Continuous Predictor Variable for DSS
Because tumor size is such a critical parameter by which STSs are staged in each edition of the AJCC staging system, the relationship between the log hazard and tumor size was investigated. Coefficients for HRs from Cox proportional hazard models of DSS were calculated using multivariable restricted cubic splines and multivariable fractional polynomial regression adjusted for all covariates listed in supplemental eTable 3. Predicted log HRs for tumor size from the linear and nonlinear models are plotted in Figure 1 , which demonstrates a biphasic effect of tumor size on adjusted HRs for DSS. The effect of increasing size is greatest for tumors up to 8 cm, with a log-linear effect of smaller magnitude for larger tumors. The AJCC 8th edition T categories also reflect these findings, showing decreasing contrasts between T categories with increasing tumor size.
Tumor Depth as an Independent Prognostic Factor
Another difference among previous AJCC staging systems is consideration of tumor depth (superficial or deep to superficial fascia). Comparison of superficial and deep tumors in multivariable regression demonstrated that deep tumors confer a 55% increased risk for sarcoma-specific death after accounting for confounding covariates (95% CI, 35%-78%; P<.0005; supplemental eTable 3). Predicted HRs for sarcoma-specific survival by tumor depth and histologic grade after adjusting for interactions between tumor depth and size and the presence or absence of metastasis show that for intermediate-and highgrade tumors, anatomic depth contributes significant prognostic information (Figure 2 ).
Prognostic Impact of LNM
Categorization of LNM is inconsistent across different AJCC staging editions, probably because nodal metastasis is relatively uncommon for STS (supplemental eTable 2). Regardless, evidence from the SEER database suggests that nodal and distant metastatic disease should not be combined as stage IV disease. After controlling for covariates, pairwise comparison of HRs showed significant differences between distant and nodal metastasis (HR, 1.60; 95% CI, 1.18-2.16; P=.002), as well as between nodal metastasis and localized sarcomas (HR, 2.88; 95% CI, 2.19-3.80; P<.0005; Figure 3 ).
Derivation of a Revised Staging Scheme
Considering these potential issues with the AJCC 8th edition staging system, a revised staging system was derived based on assessment of the relative impact of predictive factors. Using nomographic techniques, histologic grade, tumor size, and distant metastasis were confirmed to have profound effects on DSS (supplemental eFigure 1). Given the relationship between tumor size and its adjusted log HR (Figure 1 ), the AJCC 8th edition T3 (>10 cm and ≤15 cm) and T4 (>15 cm) categories were combined. Lymph node status was considered separately from distant metastasis as well (Figure 3 ). Other potential anatomic pre- dictive factors evaluated included tumor depth and location. Anatomic depth showed a slightly greater predictive potential than anatomic location in multivariable Cox regression models (supplemental eTable 3 and eFigure 1), and therefore this variable was incorporated into the proposed staging algorithm.
The Vanderbilt staging system for STS of the extremity and trunk (Table 1) was then developed from empirical observations of sarcoma-specific survival of cases classified by histologic grade, modified AJCC 8th edition T classification, anatomic depth, and nodal or distant metastasis (supplemental eFigure 2 and eTable 4). In contrast to the AJCC 7th and 8th edition staging systems, the Vanderbilt staging system for STS separates patients into 5 relatively evenly distributed prognostic groups ( Table 2) .
Comparison of Vanderbilt Staging System Versus AJCC Editions
The 7th and 8th editions of the AJCC staging system for STSs were then compared with the Vanderbilt staging system to determine which, if any, is most predictive of patient outcome. Visual inspection of Kaplan-Meier plots for DSS showed poor separation for stages IA and IB in the AJCC 8th edition staging system (Figure 4) . Likewise, stages IA and IB and stages IIA and IIB in the AJCC 7th edition staging system show poor discriminative ability. In contrast, the Vanderbilt staging system shows significant contrast between each adjacent stage group ( Figure  4 ). Pairwise comparison of HR coefficients confirm these impressions (Table 3) .
Predictive Ability for 5-Year DSS
Next, the capability of each staging system to predict 5-year survival was assessed by logistic regression using the subset of cases not missing values for any of the examined staging systems (supplemental eTable 5). In this subset, 3,365 patients survived at least 5 years after diagnosis and 1,914 (36%) died within 5 years of initial diagnosis. ROC curves generated from logistic regression models ( Figure 5 ) showed good predictive ability for each AJCC staging system (AJCC 8th edition, 78.9% [SE, 0.6%]; AJCC 7th edition, 78.6% [SE, 0.6%]) compared with a simple predictive model containing information only on the presence of nodal or distant metastasis at diagnosis (63.0% [SE, 0.6%]). However, the Vanderbilt staging system showed significantly higher accuracy (80.4% [SE, 0.6%]) than both AJCC staging systems (P<.00005).
Comparison of Concordance Indices and Measures of Model Fit
The Vanderbilt staging system showed significantly higher concordance with clinical outcomes than the AJCC staging systems for 2 of the 3 indices calculated ( were highest with the Vanderbilt staging system. This proposed staging system was also associated with the lowest Bayesian information criterion, suggesting that of these 3 regression models, the Vanderbilt staging system generates the best-fitting model.
Sensitivity Analysis
Because some of the statistical analyses were performed using only cases without missing data for staging variables, sensitivity analysis was performed on a subset of cases diagnosed between 2000 and 2013 (n=17,096). No marked differences were obtained for any of the results. The number of patients with discordant stage assignments and the corresponding sarcoma-specific survival rates are presented in supplemental eTables 6 and 7.
Discussion
Prognostic stratification of STS using the AJCC TNM staging system is difficult because of the wide distribution of anatomic sites affected by sarcoma, the diverse biological behaviors of different histologic subtypes of sarcoma, the relative infrequency of LNM, and the perceived necessity of dichotomizing or otherwise categorizing a continuous variable (size) as a primary staging criterion. 21, 34 The first of these problems is now rectified in the 8th edition of the AJCC Cancer Staging Manual, 1 which provides separate staging algorithms for sarcomas of the extremity and trunk, retroperitoneum, or head/neck regions. However, whether the latest AJCC staging system for sarcomas of the extremity and trunk is an improvement compared with previous editions concerning the other aforementioned problems is unclear. The results of this study suggest that it is not.
Multiple statistical analyses failed to disclose any suggestion of improved clinical performance associated with the 8th edition of the AJCC staging system. This is rather disappointing, particularly considering the loss of data recorded in the new system (tumor depth) as well as the cost in time and effort incurred by physicians and tumor registrars in converting their reporting practices to the new AJCC system. In contrast, a proposed staging system incorporating anatomic depth, slightly modifying AJCC 8th edition T categories, and separating cases with LNM from those with distant metastasis (as in the AJCC 7th edition) does show significant improvement in predicting 5-year survival and model concordance.
A major problem with all AJCC STS staging systems is reliance on dichotomization or categorization of tumor size. 2, 13, [35] [36] [37] [38] [39] [40] Categorizing continuous data generates regression coefficients weighted by the distribution of data within each category, which almost always fails to capture the true nonlinear relationship between a continuous variable and its log hazard. 21 This caveat aside, although T categorization in the AJCC 8th edition staging system seems to recapitulate the nonlinear effect of tumor size, subcategorization of tumors >10 cm in dimension does not increase prognostic utility. Until an adequate surrogate for primary tumor growth and/or extension is implemented in the sarcoma staging system, this issue will remain one of the foremost challenges in prognostication of STS. One possible alternative is Enneking et al's concept of compartmental status, in which a sarcoma is considered intracompartmental if "within a well-delineated anatomic compartment" defined by "major fascial septae and the tendinous origins and insertions of muscles in soft tissues." 13 Conversely, extracompartmental tumors "diffusely [infiltrate] poorly demarcated adventitial planes and spaces" or arise within "ill-defined interfascial spaces and planes…limited only by loose areolar tissues that favor occult microextension." 13 Analysis of compartmental status could not be performed in this study because data regarding local tumor extension are poorly documented for STS in the SEER database. At this point, the Enneking staging system has not been tested thoroughly in staging STS.
Another problem with the AJCC 7th and 8th editions is the disregard for independent prognostic information provided by tumor depth. Deep tumors are associated with worse outcomes than superficial ones, even after controlling for tumor size and histologic grade. 2, 9, 36, [41] [42] [43] Finally, there is no rationale for staging lymph nodes as equivalent to distant, nonnodal metastasis. In the current study, sarcomas associated with nodal metastasis showed significantly lower risk of disease-specific death than distant, nonnodal metastases. Other investigators have reported similar findings. 2, 44, 45 Regardless, risk stratification of LNM is not likely a major factor affecting the performance of prognostic models because <5% of patients with sarcoma present with nodal metastasis.
The current AJCC staging scheme may also be improved through stratification by histologic risk group, because histologic subtype remains an inde- 38 In the future, the AJCC might also consider incorporating pertinent prognostic genomic/molecular data as it becomes available. 48 The strengths of the SEER database are its size, established quality assurance program, and internal and external validity. 49, 50 It is therefore a useful tool by which to validate or compare different staging algorithms. 50 There are some drawbacks to using the SEER database, however. 51 It does not allow for evaluation of disease-free survival because time to local or distant disease recurrence is not available. Extracting relevant data from historical variables regarding extent of disease is difficult. 52 Continued use of the Collaborative Stage schema (https:// cancerstaging.org/cstage) for recording local extent of disease should allow for a detailed assessment of this predictive factor and application of the staging principles Enneking et al advocated in future studies. Data regarding neoadjuvant and adjuvant therapy, which is important to consider in studies of patient outcome, are less robust than other recorded variables in the SEER database. The accuracy of SEER data on histologic diagnosis and Fédération Nationale des Centres de Lutte Contre le Cancer (FN-CLCC) grade is also debatable given the lack of central review by expert soft tissue pathologists. Because sarcoma subtype diagnosis may be unreliable in the SEER database, this variable was not considered in this analysis. In addition, many database records lack data for one or more variables. For example, tumor stage in the Vanderbilt staging system could not be derived for more than half of SEER cases because of missing data. Therefore, sensitivity analysis was performed on the subset of cases diagnosed between 2000 and 2013. Marked differences in results were not observed, suggesting that missing data did not cause significant analytical bias.
Conclusions
Site-specific staging systems in the 8th edition of the AJCC Cancer Staging Manual resolve a major problem heretofore unaddressed in staging STSs. Although the data presented here show that the new site-specific staging system for extremity and trunk sarcomas performs no better than the previous nonsite-specific version, this does not necessarily invalidate the merit or utility of anatomic site-specific staging systems. Separate staging systems for different anatomic sites may be an important first step in improving the staging of STS in general. Clearly, the current staging system can be improved by including additional important predictor variables, as demonstrated with the Vanderbilt staging system. Alternatively, a staging system incorporating histologic risk group might also result in better risk stratification. At the very least, the AJCC should not issue broad mandatory changes in staging algorithms without evidence that such changes improve clinical and pathologic staging.
